Apimeds Pharmaceuticals (APUS) Stock Analysis: AI Score & Alternative Data
APUS alt-data: web traffic climbing, sentiment lagging
Is Apimeds Pharmaceuticals a buy right now? The alternative data says hold. This APUS stock analysis is built on the 25+ alternative data signals AltIndex tracks on Apimeds Pharmaceuticals every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $4.04 with a $6M market cap.
The bullish side of the 90-day ledger: web traffic up 18.6% to 511 monthly visits. The drag: sentiment down 15.0% to 85/100. That tension is what keeps the score mid-range.
APUS’s broader alt-data profile also covers headcount (11 employees, according to LinkedIn), and X followers (6K). Every signal links to its own page with full history, the APUS technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on APUS is just below.
Apimeds Pharmaceuticals AI Stock Analysis
Apimeds Pharmaceuticals is a leading player in the pharmaceutical industry, dedicated to developing innovative medications that cater to unmet medical needs. With a strong portfolio of products and a commitment to research and development, the company aims to enhance patient outcomes and provide value to its shareholders.
Analysis generated October 6, 2026.
Recent Apimeds Pharmaceuticals Stock Alerts
|
Apimeds Pharmaceuticals | October 16 Price is down by -6.2% in the last 24h. |
|
Apimeds Pharmaceuticals | October 15 Price is down by -6.3% in the last 24h. |
|
Apimeds Pharmaceuticals | October 14 Price is down by -6.3% in the last 24h. |
|
Apimeds Pharmaceuticals | October 13 Twitter followers are down by 2% in the last 24h. |
Apimeds Pharmaceuticals Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 511 | 18.6% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 11 | 0% | |
| Sentiment | 85 | 15.0% | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 96.4% | |
| Stocktwits Mentions | 67 | 857.1% | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 1K | 197.7% | |
| X Followers | 6K | 16.3% |
About Apimeds Pharmaceuticals (APUS)
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company in the United States. The company is headquartered in Hopewell, New Jersey.
| Price | $4.04 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $6M |
| Year Range | $2 – $39 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Drug Manufacturers |
Latest Apimeds Pharmaceuticals News
View more →
MindWave Innovations Inc., a Wholly Owned Subsidiary of Apimeds Pharmaceuticals US, Inc., Announces MindChain: World’s First Fully Insured Blockchain, Launching in OctoberJuly 28 - Financial Post |
|
NILA Token Now Available to Eligible U.S. Users on Webot, a Licensed U.S. Cryptocurrency ExchangeAugust 3 - Financial Post |
See Apimeds Pharmaceuticals’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for APUS, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEApimeds Pharmaceuticals Earnings & Financial Performance
View all earnings →Apimeds Pharmaceuticals Insider Trading Activity
View all →| Kim Christopher filed to sell 27,500 shares at $0.0. May 14 '25 |
| Kim Christopher filed to sell 19,770 shares at $0.0. May 13 '25 |
| Koo Jakap filed to sell 643,885 shares at $0.0. May 12 '25 |
| Inscobee Inc. filed to sell 1,984,616 shares at $0.0. May 12 '25 |
Apimeds Pharmaceuticals Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Apimeds Pharmaceuticals
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
GelteqGELS |
$0.45 3.6% | $5M | 48 |
 |
RedHill BiopharmaRDHL |
$0.48 3.8% | $4M | 36 |
 |
AkandaAKAN |
$1.20 8.4% | $3M | 36 |
 |
Sunshine BiopharmaSBFM |
$0.22 3.6% | $3M | 43 |
 |
IM CannabisIMCC |
$1.39 4.5% | $2M | 46 |
Explore Apimeds Pharmaceuticals Data
Frequently Asked Questions: Apimeds Pharmaceuticals (APUS)
Apimeds Pharmaceuticals has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Apimeds Pharmaceuticals (APUS) stock is $4.04 with a market cap of $6M.
As of today, Apimeds Pharmaceuticals’s PE (Price to Earnings) ratio is —.
View the latest Apimeds Pharmaceuticals insider transactions to see recent buying and selling activity by company executives and directors.
Check the Apimeds Pharmaceuticals congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The APUS stock price chart above shows Apimeds Pharmaceuticals’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Apimeds Pharmaceuticals technical analysis for RSI, moving averages, and more.
See the stocks similar to Apimeds Pharmaceuticals section on this page for companies in the same industry ranked by market cap and AI Score.
